Hyperuricemia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for hyperuricemia including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.

Overview of the drug development pipeline for hyperuricemia

It has been observed that hyperuricemia is a condition where the uric acid in the blood level increases. The uric acid passes through the liver and enters the bloodstream. Most of it is excreted through urine or passes through the intestines (to maintain the normal level). The normal uric acid levels are 2.4-6.0 mg/dL in females and 3.4-7.0 mg/dL in males. Purines are also important to regulate the blood uric acid levels. The common symptoms of hyperuricemia include pain while urinating, nausea, increased urge to urinate, joint stiffness, and blood in the urine. A high level of uric acid is a causative factor in gout and urolithiasis. Several public and private companies are focused on the development of drug molecules for the treatment of hyperuricemia. Monotherapy is emerging as the most efficient approach for the treatment of hyperuricemia.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for hyperuricemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Pipeline analysis report on drug development for hyperuricemia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperuricemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Allena Pharmaceuticals
• CymaBay Therapeutics
• Fuji Yakahin

Therapeutic assessment of the drug development pipeline for hyperuricemia by route of administration

• Oral
• Intravenous
• Unknown

The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells. The intravenous ROA is done by delivering the drug molecules through the veins.

Therapeutic assessment of the drug development pipeline for hyperuricemia by therapy

• Monotherapy
• Combination Therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for hyperuricemia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug therapy molecules in the various development stages for hyperuricemia?
• What are the companies that are currently involved in the development of drug molecules for hyperuricemia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.